--- title: "\"Major Banks\" CMB International's Investment Ratings and Target Prices for Pharmaceutical Stocks (Table)" type: "News" locale: "en" url: "https://longbridge.com/en/news/245641399.md" description: "China Merchants Jinling International released a research report listing investment ratings and target prices for pharmaceutical stocks. AstraZeneca is rated as Buy, with a target price of $93.3; Beigene is rated Buy, with a target price of HKD 208.8; Hansoh Pharmaceutical is rated Buy, with a target price of HKD 33; Innovent Biologics is rated Buy, with a target price of HKD 84; SINO BIOPHARM is rated Buy, with a target price of HKD 5.9; Kelun-Bio is rated Buy, with a target price of HKD 400; Legend Biotech is rated Buy, with a target price of $65; WuXi AppTec is rated Buy, with a target price of HKD 51; Hutchison China MediTech is rated Buy, with a target price of HKD 44; Sihuan Pharmaceutical is rated Buy, with a target price of HKD 14.3; THDB is rated Buy, with a target price of RMB 14; Genting Yongying is rated Buy, with a target price of HKD 65; ConvaTec-B is rated Buy, with a target price of HKD 57; Jinxin Fertility is rated Buy, with a target price of HKD 3.75; Genscript Biotech is rated Buy, with a target price of HKD 42; Heng Rui Medicine is rated Neutral, with a target price of RMB 51; CSPC Pharmaceutical Group is rated Neutral, with a target price of HKD 7.2; Kelun Pharmaceutical is rated Neutral, with a target price of RMB 40.2; Bristol-Myers Squibb is rated Sell, with a target price of $33.1" datetime: "2025-06-23T07:11:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/245641399.md) - [en](https://longbridge.com/en/news/245641399.md) - [zh-HK](https://longbridge.com/zh-HK/news/245641399.md) generator: "portal-rs" --- # "Major Banks" CMB International's Investment Ratings and Target Prices for Pharmaceutical Stocks (Table) China Merchants Jinling International published a research report, listing the investment ratings and target prices for pharmaceutical stocks as follows: Stock | Investment Rating | Target Price AstraZeneca (AZN.US) | Buy | $93.3 Beigene (06160.HK) | Buy | HKD 208.8 Hansoh Pharmaceutical (03692.HK) | Buy | HKD 33 Innovent Biologics (01801.HK) | Buy | HKD 84 SINO BIOPHARM (01177.HK) | Buy | HKD 5.9 Kintor Pharmaceutical-B (06990.HK) | Buy | HKD 400 Legend Biotech (LEGN.US) | Buy | $65 WuXi AppTec (02268.HK) | Buy | HKD 51 Hutchison China MediTech (00013.HK) | Buy | HKD 44 Sihuan Pharmaceutical (02096.HK) | Buy | HKD 14.3 THDB (600867.SH) | Buy | RMB 14 Genscript Biotech (01952.HK) | Buy | HKD 65 CanSino Biologics-B (02162.HK) | Buy | HKD 57 Jinxin Fertility (01951.HK) | Buy | HKD 3.75 Guangzhou Pharmaceutical (02273.HK) | Buy | HKD 42 Hengrui Medicine (600276.SH) | Neutral | RMB 51 Shijiazhuang Pharmaceutical Group (01093.HK) | Neutral | HKD 7.2 Kangmei Pharmaceutical (002422.SZ) | Neutral | RMB 40.2 Bristol-Myers Squibb (BMY.US) | Sell | $33.1 ### Related Stocks - [BGNE.US](https://longbridge.com/en/quote/BGNE.US.md) - [688235.CN](https://longbridge.com/en/quote/688235.CN.md) - [06160.HK](https://longbridge.com/en/quote/06160.HK.md) - [01177.HK](https://longbridge.com/en/quote/01177.HK.md) - [LEGN.US](https://longbridge.com/en/quote/LEGN.US.md) - [600867.CN](https://longbridge.com/en/quote/600867.CN.md) - [01801.HK](https://longbridge.com/en/quote/01801.HK.md) - [01952.HK](https://longbridge.com/en/quote/01952.HK.md) - [03692.HK](https://longbridge.com/en/quote/03692.HK.md) - [002422.CN](https://longbridge.com/en/quote/002422.CN.md) - [01276.HK](https://longbridge.com/en/quote/01276.HK.md) - [02273.HK](https://longbridge.com/en/quote/02273.HK.md) - [00013.HK](https://longbridge.com/en/quote/00013.HK.md) - [01093.HK](https://longbridge.com/en/quote/01093.HK.md) - [AZN.US](https://longbridge.com/en/quote/AZN.US.md) - [01951.HK](https://longbridge.com/en/quote/01951.HK.md) - [02096.HK](https://longbridge.com/en/quote/02096.HK.md) - [02268.HK](https://longbridge.com/en/quote/02268.HK.md) - [600276.CN](https://longbridge.com/en/quote/600276.CN.md) - [BMY.US](https://longbridge.com/en/quote/BMY.US.md) - [03329.HK](https://longbridge.com/en/quote/03329.HK.md) ## Related News & Research - [Will Legend Biotech’s (LEGN) Move to Q2 Profitability Reshape Its Investment Narrative?](https://longbridge.com/en/news/296957090.md) - [Sino Biopharma wins FDA clearance to start trial of CPX301 GLP-1 weight-loss microneedle patch](https://longbridge.com/en/news/296857285.md) - [SBP GROUP 's Innovative ActRII A/B Monoclonal Antibody Approved for Clinical Study](https://longbridge.com/en/news/296699167.md) - [Sino Biopharm says NMPA clears TQF6422 obesity drug candidate for clinical trial](https://longbridge.com/en/news/296603125.md) - [Sino Biopharma rebrands as SBP Group, targets global expansion via direct commercial rollout and partnerships](https://longbridge.com/en/news/296447837.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**